Center-Authored Papers

Filters: Author is Chan, Daniel W  [Clear All Filters]
Journal Article
McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J et al..  2008.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.. Clinical chemistry. 54(1):44-52. Abstract
Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH et al..  2017.  Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.. JAMA oncology. Abstract
Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby EJ et al..  2014.  Can urinary PCA3 supplement PSA in the early detection of prostate cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(36):4066-72. Abstract
Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J et al..  2013.  The impact of prostate volume, number of biopsy cores, and AUA symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial Risk Calculator.. The Journal of urology. Abstract
Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, Gillette MA, Clauser KR, Qiao JW, Gritsenko MA, Moore RJ et al..  2014.  Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.. Molecular & cellular proteomics : MCP. Abstract
Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT et al..  2010.  A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(5):1193-200. Abstract
Wang J, Ma Z, Carr SA, Mertins P, Zhang H, Zhang Z, Chan DW, Ellis MJC, Townsend RR, Smith RD et al..  2016.  Proteome profiling outperforms transcriptome profiling for co-expression based gene function prediction.. Molecular & cellular proteomics : MCP. Abstract
Hoofnagle AN, Whiteaker JR, Carr SA, Kuhn E, Liu T, Massoni SA, Thomas SN, Townsend RR, Zimmerman LJ, Boja E et al..  2016.  Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays.. Clinical chemistry. 62(1):48-69. Abstract
McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J et al..  2008.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.. Clinical chemistry. 54(1):53-60. Abstract
Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L et al..  2012.  Updating risk prediction tools: A case study in prostate cancer.. Biometrical journal. Biometrische Zeitschrift. 54(1):127-142. Abstract
Whiteaker JR, Halusa GN, Hoofnagle AN, Sharma V, Maclean B, Yan P, Wrobel JA, Kennedy J, Mani DR, Zimmerman LJ et al..  2016.  Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.. Methods in molecular biology (Clifton, N.J.). 1410:223-36. Abstract
Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW.  2008.  [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.. The Journal of urology. 180(2):539-43;discussion543. Abstract